Small Pharmacies Accuse FDA of Favoring Big Pharma over Consumers in Weight Loss Drug Decision
The FDA is under fire over a recent decision to declare an end to the shortage of semaglutide and tirzepatide, the active ingredients in popular weight-loss and diabetes medications collectively known as GLP-1 drugs. The decision hurts small pharmacies while helping pharma giants like Novo Nordisk.
